Curis (FRA:CUS0) Short Interest


FRA:CUS0 Curis Inc FRA:CUS0
49 GF Score
Price €0.37
GF Value €1.07
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Curis Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:CUS0 vs HOWL, TRAW, CVM: Short Interest Comparison

For the Biotechnology subindustry, Curis's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curis Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curis's Short Interest distribution charts can be found below:

* The bar in red indicates where Curis's Short Interest falls into.


FRA:CUS0
49GF Score
Curis Inc FRA:CUS0
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Curis (FRA:CUS0) Overvalued in 2026?

Based on GuruFocus' analysis, Curis stock appears to be undervalued. The current stock price of €0.37 is trading 65.2% below its estimated GF Value™ of €1.07. GuruFocus considers Curis to be Possible Value Trap.

Key valuation signals for FRA:CUS0:

  • Short Interest:
  • GF Value™: €1.07 vs. price of €0.37 (65.2% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the FRA:CUS0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Curis Business Description

Other Exchanges CRIS:USA
Address 128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
49GF Score

Get the complete analysis for FRA:CUS0

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.37
Price
€1.07
GF Value